Key result
Aspirin discontinuation resolves bleeding events in HeartMate 3 patients on VKA monotherapy.
Why the study?
Does aspirin discontinuation improve the resolution of bleeding events in HeartMate 3 patients?
Does aspirin discontinuation improve the resolution of bleeding events in HeartMate 3 patients?
Aspirin discontinuation may be an effective strategy to manage and resolve bleeding complications in patients with HeartMate 3 devices receiving warfarin.
May support aspirin omission for bleeding resolution in HM3 on VKA; hypothesis-generating, requires randomized confirmation before practice change.
Therapy in Patients with the HeartMatE II (EU TRACE study) demonstrated that bleeding complications in patients receiving the HeartMate II (Thoratec Corp., Pleasanton, CA, USA) can be managed with reduced antithrombotic therapy, particularly with aspirin discontinuation.4 Similarly, Lim et al. 5 showed that aspirin discontinuation allowed resolution of bleeding events in HM3 patients on a single vitamin-K antagonist (warfarin
No takes yet. Share an insight, caveat, or question.
Consolo et al. (2019) studied HeartMate 3 patients. Aspirin discontinuation was evaluated. Aspirin discontinuation allowed resolution of bleeding events in HeartMate 3 patients on a single vitamin-K antagonist.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: